Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Teva and Sanofi Accelerate Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease
Jul 25, 2024
Contract Type
partnership
Tel AvivManufacturingBiotechnologyHealth CareTherapeuticsPharmaceutical
Description
Teva and Sanofi have announced an accelerated timeline for the anti-TL1A program, including the completion of patient enrollment in the RELIEVE UCCD Phase 2b trial and the update to the timing for topline and detailed results. They are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients.
Company Information
Company
Teva Pharmaceutical Industries Ltd
Location
Tel Aviv, Tel Aviv District, Israel
About
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of people worldwide. With a focus on innovative medicines, especially in areas of central nervous system, pain, and respiratory therapies, Teva is dedicated to improving health and increasing access to medicines around the world.